Track topics on Twitter Track topics that are important to you
MALVERN, Pa., March 06, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at the following investor conferences in March.
Cowen and Company 38th Annual Health Care Conference
Location: Marriott Copley Place, Boston
Date / Time: Tuesday, March 13, at 11 a.m. EDT
Needham & Company 17th Annual Healthcare Conference
Location: Westin New York Grand Central, New York City
Date / Time: Tuesday, March 27, at 9:30 a.m. EDT
PhaseBio Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases. PhaseBio is leveraging its proprietary elastin-like polypeptide (ELP) biopolymer technology platform to develop therapies with the potential for less-frequent dosing and better patient compliance. PhaseBio’s lead development candidate, PB1046, is a first-in-class weekly vasoactive intestinal peptide (VIP) receptor agonist for the treatment of pulmonary arterial hypertension. The company is also developing PB2452, a reversal agent for the antiplatelet therapy ticagrelor. PhaseBio is privately owned, with headquarters and research laboratories in Malvern, PA. For more information, please visit www.phasebio.com.
Laura Bagby, 6 Degrees
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...